Related references
Note: Only part of the references are listed.Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
S. V. Antunes et al.
HAEMOPHILIA (2014)
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey
M. Franchini et al.
HAEMOPHILIA (2014)
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Jan Astermark et al.
BLOOD (2013)
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw et al.
BLOOD (2013)
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
Peter W. Collins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?
G. Di Minno et al.
HAEMOPHILIA (2013)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment
A. Farrugia et al.
HAEMOPHILIA (2013)
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update
Massimo Franchini et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
FEIBA versus NovoSeven in Hemophilia Patients with Inhibitors
Massimo Franchini et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Char Witmer et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Charles R. M. Hay et al.
BLOOD (2012)
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw et al.
BLOOD (2012)
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A
M. E. Mancuso et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges
Antonio Coppola et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors
A. Gringeri et al.
HAEMOPHILIA (2011)
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Cindy Leissinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy
A. Giampaolo et al.
TRANSFUSION MEDICINE (2011)
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches
Antonio Coppola et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Cost of care of haemophilia with inhibitors
Matteo Nicola Dario Di Minno et al.
HAEMOPHILIA (2010)
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
A. Iorio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors
A. Coppola et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Italian registry of haemophilia and allied disorders.: Objectives, methodology and data analysis
A. Iorio et al.
HAEMOPHILIA (2008)
European Study on Orthopaedic Status of haemophilia patients with inhibitors
M. Morfini et al.
HAEMOPHILIA (2007)
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
B. A. Konkle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response
A. Gringeri et al.
HAEMOPHILIA (2007)
International workshop on immune tolerance induction: consensus recommendations
D. M. Dimichele et al.
HAEMOPHILIA (2007)
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
Samantha C. Gouw et al.
BLOOD (2007)
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
J. Astermark et al.
HAEMOPHILIA (2007)
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
J Goudemand et al.
BLOOD (2006)
Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors
A Gringeri et al.
HAEMOPHILIA (2005)
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study
E Santagostino et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99
SC Darby et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
A Gringeri et al.
BLOOD (2003)
The epidemiology of inhibitors in haemophilia A: a systematic review
J Wight et al.
HAEMOPHILIA (2003)
Share Paper
